Kelun Group a 2015 Fortune 500 company in China, with 30000 staffs in 90+ subsidiaries, offers over 520 products and is the market leader of injectable and infusion technologies. Kelun Group´s revenues in 2015 exceeded RMB 39 billion, or USD 6 billion. Kelun Pharmaceutical is committed to R&D for small-molecule NCEs and biological NBEs, biosimilars, generic drugs, and new drug delivery systems (NDDS) in oncology, diabetes, hepatitis, cardiovascular and other major disease areas.
Kelun Pharmaceutical Research Institute, headquartered in Sichuan Chengdu, with the subsidiary pharmaceutical research institutes at Tianjin, Suzhou and the Kelun US Pharmaceutical Research Institute，that manages Kelun US operation and Klus Pharma, has more than 990 people. Thomson Reuters in 2014 ranked Kelun the 4th most competitive pharm product pipeline in China.